Facet Life Sciences https://validator.w3.org/feed/docs/rss2.html Understanding the Different Types of Gap Analysis in Life Sciences Blogs Home William (Bill) Hodnick, Ph.D., DABT Ken Vanluvanee Dana Blue, M.S. Jason Mercer, Ph.D., RAC Catherine (Cathy) Kessler Lisa Jenkins Vanluvanee, Ph.D. About Facet Life Sciences Drug Development Consulting Services Contact Us Thomas W. Meyer Gap Analysis Services Publications Michelle Byrne, BME, RAC Jamie Chambers, RAC Justin Leng, PharmD Marcoita Gilbert, Ph.D., DABT Josh Eldridge, Ph.D. Venita DePuy, Ph.D. Importance of Asset Valuation in Pharmaceutical Research and Development Our Partners Identifying and Closing Gaps Before NDA Filing Careers Meredith Scarberry, MS Amanda Austin, MD Tom Hallam, Ph.D., MBA Kristen Harrington Michael Tomasovich, MS RAC Morgan Waad, MS Scott Burian, Ph.D. RAC Sarah Woodruff Nikole Santos Randy Goodman, Ph.D., MHA, FACHE, PMP, BCMAS Dominique Canlas CAREER OPPORTUNITIES Why Do You Need a Life Sciences Product Landscape Assessment? PDUFA User Fees- Impact On Your Submission Facet Life Sciences and XCancer Announce Strategic Partnership to Advance Theranostic Clinical Trials FDA Meeting Consulting Radiopharmaceuticals Leveraging Development Opportunities in Radiopharmaceuticals Psychedelics Regulatory How Do I Determine Good Regulatory Guidance? Robert Vollkommer, MBA Behind the Scenes of an FDA Type C Meeting: A Case Study in Using Gap Analysis to Align Nonclinical Strategy in a Rare Pediatric Disease Navigating the CMC Journey in Radiopharmaceuticals Eva Raspor, MSc